

**Fortis Healthcare Limited**

Corporate Office:

Tower A, Unitech Business Park,
Block- F, South City 1, Sector-41,
Gurgaon, Haryana - 122 001 (India)

Tel : +91 124 4921 021

Fax : +91 124 4921 041

Ambulance : 105010

E-mail : contactus@fortishealthcare.comWebsite : www.fortishealthcare.com

September 12, 2014

The National Stock Exchange of India Ltd.
Corporate Communications Department
"Exchange Plaza", 5th Floor,
Bandra-Kurla Complex, Bandra (East),
Mumbai – 400051BSE Limited
Corporate Services Department
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001

Scrip Symbol: FORTIS

Scrip Code:532843

Sub: Divestment of Radlink-Asia Pte

Dear Sir(s),

The Board of Fortis Healthcare Singapore Pte. Ltd. which is a subsidiary of Fortis Healthcare International Pte. Ltd., one of our step down subsidiaries based out of Singapore, has decided to divest 100% shareholding in RadLink-Asia Pte Limited and its subsidiaries, to **Medi-Rad Associates Limited** for **SGD 137 million**. The deal is subject to regulatory approvals in Singapore.

A copy of the Press Release, on the subject being issued by the Company, is enclosed for your reference and records.

Thanking you.

Yours faithfully,

For Fortis Healthcare Limited
Rahul Ranjan
Company Secretary

FORTIS HEALTHCARE LIMITED

Regd. Office: Escorts Heart Institute and Research Centre, Okhla Road, New Delhi - 110 025 (India)

Tel: +91 11 2682 5000, Fax: +91 11 4162 8435, CIN: L85110DL1996PLC076704

PRESS RELEASE

Fortis to realise value from divestment of stake in RadLink-Asia Pte Ltd to Medi-Rad Associates Ltd for SGD137,000,000

Intensifies Focus on Healthcare Delivery in India

Gurgaon, India, September 12, 2014 - Fortis Healthcare Singapore Pte. Ltd., a subsidiary of Fortis Healthcare International Pte. Ltd., one of our step-down subsidiaries in Singapore, today announced its decision to divest 100% shareholding in RadLink-Asia Pte Ltd and its subsidiaries, “RadLink”, Singapore, to Medi-Rad Associates Ltd (Medi-Rad), an indirect wholly-owned subsidiary of IHH Healthcare Berhad, for **SGD 137,000,000**. RadLink is engaged in the provision of healthcare services including the provision of outpatient diagnostic and molecular imaging services in Singapore. The offer price is reflective of the value and efficiencies added by the Fortis group.

The deal will be successfully closed following the necessary statutory and regulatory approvals as per local requirements.

Malvinder Singh, Executive Chairman, and Shivinder Singh, Executive Vice Chairman, Fortis Healthcare Limited, said “This is in line with our strategic decision to intensify our focus on our core hospital and diagnostics business in India. Our international healthcare businesses have all done well. The significant value that we have created, is now being unlocked and will be ploughed back to strengthen our growth in India.

“Singapore will always remain strategic and integral to our business plans for the future. We are committed to grow the relationships and partnerships that we have established here, the most prominent being our association with the Economic Development Board of Singapore (EDB) and the SGX listed Religare Healthcare Trust.”

During fiscal year 2014, Fortis added over 800 beds to its network in India. In May 2013, it launched its flagship, the Fortis Memorial Research Institute in Gurgaon and in January 2014, it commissioned a 260 bed facility in Ludhiana. A large facility in Chennai (Arcot Road) is also nearing completion and is expected to be commissioned in the next few months.

J. P. Morgan and Religare Capital Markets acted as financial advisors to Fortis for this transaction.

About Fortis Healthcare Limited

Fortis Healthcare Limited is a leading integrated healthcare delivery service provider in India. The healthcare verticals of the company primarily comprise hospitals, diagnostics and day care specialty facilities. Currently, the company operates its healthcare delivery services in India, Singapore, Dubai, Mauritius and Sri Lanka with 66 healthcare facilities (including projects under development), over 10,000 potential beds and 282 diagnostic centres. In a global study of the 30 most technologically advanced hospitals in the world, its flagship, the Fortis Memorial Research Institute' (FMRI), was ranked No.2, by 'topmastersinhealthcare.com, and placed ahead of many other outstanding medical institutions in the world.

DISCLAIMER

This press release may contain forward-looking statements based on the currently held beliefs and assumptions of the management of the Company, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this press release are cautioned not to place undue reliance on these forward-looking statements. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent development, information or events, or otherwise. The information contained herein is subject to change without notice and past performance is not indicative of future results. The Company may alter, modify or otherwise change in any manner the content of this press release, without obligation to notify any person of such revision or changes.

For information please contact:

Raghu Kochar
Corporate Communications
+91-9811617256
raghu.kochar@fortishealthcare.com

Anurag Kalra
Investor Relations
+91-9810109253
anurag.kalra@fortishealthcare.com